Tyme Technologies, Inc.

NasdaqCM:TYME Stock Report

Market Cap: US$53.5m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Tyme Technologies Past Earnings Performance

Past criteria checks 0/6

Key information

-6.90%

Earnings growth rate

5.40%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth raten/a
Return on equity-32.63%
Net Marginn/a
Last Earnings Update30 Jun 2022

Recent past performance updates

No updates

Recent updates

Seeking Alpha • Sep 15

Syros, Tyme Technologies jump more than 20% after hours as shareholders approve merger

Shareholders of Syros Pharmaceuticals (NASDAQ:SYRS) and Tyme Technologies (NASDAQ:TYME) on Thursday voted in favor of the merger between the two biotech companies. SYRS and TYME stock gained more than 20% each in aftermarket trading - SYRS +22% and TYME +24%. Both SYRS and TYME held special stockholder meetings to vote on the merger, the companies said in a statement. SYRS shareholders also voted in favor of the company's concurrent private investment in public equity (PIPE) financing. The closing of the merger and the PIPE financing are anticipated to take place on or around Sept. 16. Post the closing of the merger, the combined company will trade on the Nasdaq under the ticker symbol "SYRS". SYRS also announced a 1-for-10 reverse stock split, with the stock to begin trading on a split-adjusted basis on the Nasdaq on Sept. 19.
Analysis Article • Aug 05

We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Jul 05

TYME stock surges on merger agreement and Syros Pharmaceuticals

Development stage biotech firms Syros Pharmaceuticals (SYRS) and Tyme Technologies (NASDAQ:TYME) announced on Tuesday that the companies entered into a definitive merger agreement following which Syros (SYRS) will acquire Tyme (TYME). Tyme (TYME) has added ~23% in the pre-market so far while Syros (SYRS) is trading ~6% higher. Per the terms, Syros (SYRS) will issue ~74.3M shares of its common stock to TYME investors and TYME stockholders are entitled to nearly 0.4312 shares of Syros (SYRS) common stock for each TYME stock they hold. The deal is worth about $60M net of wind-down and transaction expenses. Following the merger, the combined entity will be led by Syros’ existing management team and trade on Nasdaq under the ticker symbol “SYRS.” Separately, Syros (SYRS) disclosed an oversubscribed $130M financing of private investment in public equity (PIPE) to purchase a total of up to 138.1M additional shares of common stock at $0.94 apiece. In addition, Syros (SYRS) also announced an amendment to its senior secured loan facility with Oxford Finance LLC. The terms include one year extension to the interest-only payment period and maturity dates subject to conditions revising them to March 1, 2024, and February 1, 2026, respectively. The transactions are expected to close in H2 2022.
Seeking Alpha • May 26

Tyme Technologies: Net-Net Biopharma Exploring Strategic Alternatives

Tyme Technologies is a clinical-stage biopharma company trading at a large discount to net cash + marketable securities. After the company discontinued the development of its primary compound, they have announced exploration of strategic alternatives. Board seems to be leaning towards a sale of the company.
Analysis Article • Mar 19

We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Dec 07

Tyme Technologies Offers Incredible Risk-Reward

Tyme Technologies recently reported their Q2 earnings that revealed the company only burned roughly $5M in cash with about $97M left in the bank. The small-cap sell-off has pushed the share price to fresh 52-week lows. I believe TYME has an incredible risk-reward at these prices. I review some of the company’s updates and point out a few bullish highlights for investors. In addition, I discuss some of my lingering downside risks for TYME. I update investors on my strategy for managing my TYME position and how I intend to take advantage of the sell-off.
Analysis Article • Nov 19

Here's Why We're Not Too Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 27

Tyme Technologies: The Market Missed The Bullish Memo

Tyme Technologies recently made some big moves following a strategic review. I believe the market has missed the bullish memo about these changes. I review some of these significant changes and provide a bullish memo for investors. In addition, I discuss how these changes have addressed my downside concerns. The recent sell-off provided me with an opportunity to load up near the 52-week lows. I update investors on my strategy for managing my TYME position.
Analysis Article • Jul 19

We're Not Very Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Mar 26

Here's Why We're Watching Tyme Technologies' (NASDAQ:TYME) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Feb 19

Have Tyme Technologies, Inc. (NASDAQ:TYME) Insiders Been Selling Their Stock?

Investors may wish to note that an insider of Tyme Technologies, Inc. , Michael Demurjian, recently netted US$55k from...
Analysis Article • Feb 02

Do Institutions Own Tyme Technologies, Inc. (NASDAQ:TYME) Shares?

A look at the shareholders of Tyme Technologies, Inc. ( NASDAQ:TYME ) can tell us which group is most powerful...
Analysis Article • Dec 16

Have Insiders Sold Tyme Technologies, Inc. (NASDAQ:TYME) Shares Recently?

We wouldn't blame Tyme Technologies, Inc. ( NASDAQ:TYME ) shareholders if they were a little worried about the fact...
Analysis Article • Dec 09

Is Tyme Technologies (NASDAQ:TYME) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Revenue & Expenses Breakdown

How Tyme Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqCM:TYME Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 220-241211
31 Mar 220-241013
31 Dec 210-241015
30 Sep 210-25915
30 Jun 210-261016
31 Mar 210-291017
31 Dec 200-281117
30 Sep 200-281216
30 Jun 200-281215
31 Mar 200-221313
31 Dec 190-271313
30 Sep 190-291414
30 Jun 190-291414
31 Mar 190-331515
31 Dec 180-271413
30 Sep 180-251311
30 Jun 180-231211
31 Mar 180-19119
31 Dec 170-1798
30 Sep 170-1477
30 Jun 170-1276
31 Mar 170-1596
31 Dec 160-1784
30 Jun 160-1395
31 Mar 160-1183
31 Dec 150-1244

Quality Earnings: TYME is currently unprofitable.

Growing Profit Margin: TYME is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: TYME is unprofitable, and losses have increased over the past 5 years at a rate of 6.9% per year.

Accelerating Growth: Unable to compare TYME's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TYME is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).

Return on Equity

High ROE: TYME has a negative Return on Equity (-32.63%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2022/09/16 16:47
End of Day Share Price 2022/09/16 00:00
Earnings2022/06/30
Annual Earnings2022/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tyme Technologies, Inc. is covered by 3 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Arlinda LeeCanaccord Genuity
Joshua SchimmerEvercore ISI
Swayampakula RamakanthH.C. Wainwright & Co.